Calliditas Therapeutics AB (publ) reaffirmed earnings guidance for the year ending December 31, 2024. For the year, the company expects continued revenue growth: total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
205.2 SEK | +0.10% | +0.20% | +61.29% |
06-18 | Calliditas Therapeutics Gets US Patent for Cancer Treatment Candidate | MT |
06-18 | Calliditas Therapeutics Secures US Patent for Cancer Treatment Inhibitor | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.29% | 1.05B | |
+17.03% | 9.11B | |
-24.00% | 4.44B | |
+13.37% | 4.24B | |
+31.17% | 4.03B | |
+6.41% | 2.14B | |
-34.04% | 1.9B | |
+7.56% | 1.94B | |
-0.50% | 1.64B | |
-47.93% | 1.63B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Calliditas Therapeutics AB Reaffirms Earnings Guidance for the Year Ending December 31, 2024